Hypertension and nephrology

[Remembering Professor István Czuriga MD]

KÉKES Ede, FARSANG Csaba, KISS István

APRIL 20, 2018

Hypertension and nephrology - 2018;22(02)

COMMENTS

0 comments

Further articles in this publication

Hypertension and nephrology

[Role of β-blockers, especially carvedilol in the treatment of hypertension]

PÁLL Dénes, MARODA László, ZRÍNYI Miklós

[Changes in hypertension guidelines in the past years have affected the clinical thinking about β-blockers. Authors reviewed the development of β-blockers emphasizing the differences across various active pharmaceutical agents. Different hemodynamic and metabolic effects are being discussed in details for the third ge - neration vasodilatator carvedilol. Carvedilol has no effect on cardiac output but decreases peripheral vascular resistance which results in lower blood pressure values. However, carvedilol, opposite to unfavorable effects of traditional β-blockers, has a neutral impact on both carbohydrate and lipid metabolisms. Its more advanced cardiac effects include decreased left ventricular hypertrophy and increased coronary flow reserve. Vasodilatator type β-blockers (carvedilol, nebivolol) are indicated in the combi - nation treatment of hypertension, especially when the patient has heart failure, coronary disease or suffered from a previous heart attack.]

Hypertension and nephrology

[A Letter to Our Readers]

KÉKES Ede, KISS István

Hypertension and nephrology

[Alberto Zanchetti]

FARSANG Csaba, JÁRAI Zoltán, KÉKES Ede, KISS István

Hypertension and nephrology

[Cholesterol-lowering is not the Holy Grail, but neither is the work of the devil]

BAJNOK László

[Cholesterol-lowering statins are the most tested medications in respect of the effects and side-effects. Based on these, we can safely claim that most of the negative opinions about cholesterol-lowering are not realistic. It is not a panacea, but it is proven that around a 30% of cardio- and cerebrovascular risk reducation can be achieved by their regular taking, while the incidence of side effects and risks are at least one order of magnitude lower in each patient groups. For cholesterol, there is no “normal” lab threshold or low level, only “target values”, since the mean value in the general population is high in regard of atherosclerosis (the values measured at birth and among natural people can be considered normal). Let us appreciate the cholesterol- lowering medications because we do not have a large armamentarium!]

Hypertension and nephrology

[The Editors Ask, the Expert Responds]

CSÁSZÁR Albert

All articles in the issue

Related contents

Lege Artis Medicinae

[Dr. Gizella Barát the first female dentist]

FORRAI Judit

[There is a long history of women in dentistry. Dr. Gizella Barát was the first female dentist in Hungary. She was among the first women admitted to the University in Hungary. Dr. Gizella Barát was a typical example of an emancipated, modern, wo­man, devoted to medical profession in the early 20th century. After graduation she was employed in the Polyclinic and started there her carreer at professor Armin Rott­mann. We follow her life’s story with existing however incomplete biographyc data.]

Hypertension and nephrology

[Risk of drug-drug interactions in hemodialyzed patien]

SZABÓ Alexandra, HARIS Ágnes

[Hemodialysis patients usually need large number of medications fór treatment of their multiple comorbidities. Because of the polypharmacy we have to count on several drug-drug interactions, which might necessitate modification of types and dosages of drugs, based on the patient's actual condition and current treatment. The use of anticoagulants causes everyday problems, because these drugs have high pharmacokinetics potency, and on the other hand their administration is indispensable. In our investigation we aimed to analyze the drug therapy of chronic hemodialysis patients in the Szent Margit Hospital Taraba István Dialysis Unit, and present the clinical pharmacist's role in the hospital team.]

Ca&Bone

[István Krasznai, MD]

FÖLDES János

[In memoriam - István Krasznai dr.]

Ca&Bone

[István Holló, MD, professor 1926-2007]

SZŰCS János

[In memoriam - István Holló]

Lege Artis Medicinae

[In the focus: steatohepatitis - Readers questions answered by dr. István Tornai]

TORNAI István